Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.
about
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cellsIn vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and CandidaIn vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agentsIn vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazolesIn vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virusIn-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida sppThe immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target proteinIn vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infectionCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)In vitro activity of a new polyene, SPA-S-843, against yeasts.Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus.The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review.Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurinClinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles.Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum.Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infectionInterpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingResistance of Candida species to fluconazoleAntifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study GroupFluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazolePatterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.Use of amphotericin B with azole antifungal drugs: what are we doing?Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation.Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response?Susceptibilities of Candida spp. to antifungal agents visualized by two-dimensional scatterplots of relative growthResponse to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors.Reversible fluconazole resistance in Candida albicans: a potential in vitro model.In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.Antifungal prophylaxis during neutropenia and immunodeficiencySusceptibility testing of fungi: current status of the standardization process.Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.Simple method for detecting fluconazole-resistant yeasts with chromogenic agar.Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy.
P2860
Q28343739-D4E0BF0B-7132-42D5-B01E-347278ED5440Q28344464-F279C1E6-1C71-4C71-B9BC-19B792DA28FDQ28368085-D1B331CF-2A5B-41FA-B3DD-EE7C7EE1A729Q28369009-D085546F-9829-484A-BABA-D7DE201B6041Q28369015-7A12F1A9-F6B7-4142-8DB7-424BDD45489DQ28369094-FB6020F0-E603-4E77-959B-5279A2534461Q28372154-BC57F88E-D310-41F2-8DBE-8BE1D729AA86Q28379384-B26CD3E7-5512-4319-810E-FA5B4D14E54AQ28379496-FE9F2380-2BBB-4670-A2ED-F61EB6A2D8B0Q30424017-CDCB22C7-9E52-4AA4-AA9E-CE4789A8BDBBQ30453646-0D5DE7CD-1FD5-45BC-8A0A-E126CBED4CDEQ33528384-2974228C-5B47-4B87-82C4-1A7622A271FFQ33702041-77DB860E-E42F-4EC3-AF4F-8B38AD00FAD7Q33721804-31B06076-93E4-4056-AB9E-D544463B92AEQ33762325-58A01D76-10BB-411C-BB7D-F6057C8F0048Q33788619-D720A019-FA31-43B7-9739-6FE696B11374Q33978506-C16A3546-459B-4284-9A6C-46B7B02F631FQ33980741-16A10950-E136-4BB5-9338-446BE425B305Q33981566-26749452-2958-4717-A699-B47B605AF59BQ34073047-9339C06A-8E66-433B-BE14-CACE51F4301AQ34106775-B1D9BB42-80FB-4BCE-B79D-C32A7BF76B88Q34633796-A2A695C0-A7CA-4155-8660-0B12290478CEQ34647337-AE8582C3-5D07-48DE-AE22-D3E748C9CE17Q35110522-79A6EB8E-133C-468D-94D4-6E6B0A0564F5Q35110598-A38A31A4-07A1-4732-A518-E84F2B915276Q35112281-668BF549-3C70-48E9-BC90-ACCF08517686Q35116163-200A88C3-B7BF-4577-B5C7-DFFCC4B35DBAQ35117932-BAF9764B-00AB-42D6-97A1-8CC79E21067AQ35118435-72D8A5F7-2983-46C3-92AF-B500852C45B5Q35119219-9603DE3F-5CAF-4007-A335-915B6241B7FBQ35122897-19CCC2E7-EF46-48C9-BB41-3F00DF4DDF21Q35126383-A426EBEE-B56C-4C3E-9183-7858406762DDQ35133365-D221CC8B-3B79-4797-8519-12A479CF5BA4Q35136251-0A3F9A31-47A6-4ADF-8A4D-F44DD386DC83Q35374928-ABF1521F-D079-49D3-838E-72D4D705CEA3Q35903839-5EF15836-53DD-4966-9D8C-CB08E907BAAAQ36519575-3C67FE8A-6888-46C7-A005-9858D953AE98Q36528018-34F0E7F6-684F-4DBE-8C41-47465D4B5B62Q36535673-B3EB71E2-8480-48CD-900B-4407FECCB75AQ36542243-8B5059A0-7B9D-4B36-B39D-9D1F512CB0BA
P2860
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Correlation of in vitro flucon ...... immunodeficiency virus type 1.
@ast
Correlation of in vitro flucon ...... immunodeficiency virus type 1.
@en
type
label
Correlation of in vitro flucon ...... immunodeficiency virus type 1.
@ast
Correlation of in vitro flucon ...... immunodeficiency virus type 1.
@en
prefLabel
Correlation of in vitro flucon ...... immunodeficiency virus type 1.
@ast
Correlation of in vitro flucon ...... immunodeficiency virus type 1.
@en
P2093
P2860
P356
P1476
Correlation of in vitro flucon ...... immunodeficiency virus type 1.
@en
P2093
P2860
P304
P356
10.1128/AAC.37.11.2449
P407
P577
1993-11-01T00:00:00Z